High Performance Sample Preparation Instrument

描述（由申请人提供）：我们申请来自共享仪器资助计划（S10）的资金，用于购买Covaris E210自适应聚焦声学（AFA）仪器，用于提取细胞RNA和制备测序所需的DNA。E210将缓解当前犹他大学许多正在进行的基因组项目的共同瓶颈，即为复杂的测序工作准备高质量的DNA。E210将为识别破坏神经系统功能和行为的突变提供新的策略，帮助提供来自已鉴定细胞和神经元的单细胞转录组数据，并大大提高基因组测序的吞吐量和成功率。“下一代”测序的最新技术进步极大地改变了我们的遗传学方法：使用标准技术可能难以或不可能绘制和克隆的突变现在可以通过全基因组测序来识别。使用最近获得的由犹他大学支持的Illumina基因组分析仪II (GA II)，美国国立卫生研究院资助的研究人员正在重新描述基因组，识别基因组突变和多态性，并编录转录组。DNA测序严重依赖于高质量的DNA和RNA，而传统的剪切方法会导致有限和宝贵的材料损失，并且不能制备出合适的均质DNA。因此，为了扩大我们的研究范围，同时提高测序效率，降低测序成本，我们申请资金购买Covaris E210，这将使我们能够充分控制组织破坏，细胞裂解，乳化和生产测序级DNA的过程。美国国立卫生研究院资助的研究神经传递、蛋白质运输和受体生物学的研究人员将使用该仪器。此外，该仪器将在正在进行的努力中，从罕见的锥蜗牛物种中识别新的药理化合物，这些化合物可以改变大脑和心脏的功能。这些研究将影响许多急性和慢性人类疾病，包括发育和精神健康障碍、兴奋毒性和中风综合征、退行性疾病，如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS），以及心功能障碍。

DESCRIPTION (provided by applicant): We request funding from the Shared Instrumentation Grant Program (S10) to purchase a Covaris E210 Adaptive Focused Acoustic (AFA) instrument for the extraction of cellular RNA and the preparation of DNA for sequencing. The E210 would relieve the current bottleneck that is common to many of the ongoing genome projects at the University of Utah, namely that of preparing high quality DNA for complex sequencing efforts. The E210 will enable new strategies for identifying mutations that disrupt nervous system function and behavior, help provide single cell transcriptome data from identified cells and neurons, and greatly increase the throughput and success rate of genome sequencing. Recent technological advances in "next generation" sequencing have dramatically transformed our approach to genetics: mutations that may be difficult or impossible to map and clone using standard techniques can now be identified via whole genome sequencing. Using a recently acquired Illumina Genome Analyzer II (GA II) that is supported by the University of Utah, NIH-funded researchers are characterizing genomes de novo, identifying genomic mutations and polymorphisms, and cataloguing transcriptomes. DNA sequencing is critically dependent on quality DNA and RNA and conventional shearing methods lead to unacceptable loss of limited and precious material and does not prepare suitably homogenous DNA. Therefore, to increase the scope of our research efforts while simultaneously improving the efficiency and decreasing the costs of sequencing, we request funding to purchase the Covaris E210, which will allow us to adequately control the processes of tissue disruption, cell lysis, emulsification and production of sequencing-grade DNA. NIH funded researchers who are studying neurotransmission, protein trafficking, and receptor biology will use this instrument. Additionally, this instrument will be invaluable in ongoing efforts to identify novel pharmacological compounds from rare species of Cones snails that modify the functions of the brain and heart. These studies will impact a number of acute and chronic human diseases, including developmental and mental health disorders, excitotoxicity and stroke syndromes, degenerative diseases such as Parkinson's, Alzheimer's, and amyotrophic lateral sclerosis (ALS), and disorders of cardiac function.